

Cluster Headache Syndrome - Pipeline Review, H2 2018

<https://marketpublishers.com/r/CFD01831E3BEN.html>

Date: July 2018

Pages: 55

Price: US\$ 2,000.00 (Single User License)

ID: CFD01831E3BEN

Abstracts

Cluster Headache Syndrome - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H2 2018, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.

Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome and features dormant and discontinued projects. The guide covers therapeutics under

Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Cluster Headache Syndrome - Overview
- Cluster Headache Syndrome - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cluster Headache Syndrome - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cluster Headache Syndrome - Companies Involved in Therapeutics Development
- Center Laboratories Inc
- Crossject SA
- Eli Lilly and Co
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- TrioxBio Inc
- Cluster Headache Syndrome - Drug Profiles
- fremanezumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- galcanezumab - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- MTR-108 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- pasireotide - Drug Profile
- Product Description
- Mechanism Of Action

R&D Progress

psilocybin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sumatriptan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

verapamil hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zucapsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cluster Headache Syndrome - Dormant Projects

Cluster Headache Syndrome - Product Development Milestones

Featured News & Press Releases

Jun 15, 2018: Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache

May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

Apr 17, 2018: Teva to Present New Data on Fremanezumab at 70th Annual Meeting of the American Academy of Neurology

Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cluster Headache Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Cluster Headache Syndrome - Pipeline by Center Laboratories Inc, H2 2018
Cluster Headache Syndrome - Pipeline by Crossject SA, H2 2018
Cluster Headache Syndrome - Pipeline by Eli Lilly and Co, H2 2018
Cluster Headache Syndrome - Pipeline by Novartis AG, H2 2018
Cluster Headache Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2018
Cluster Headache Syndrome - Pipeline by TrioxBio Inc, H2 2018
Cluster Headache Syndrome - Dormant Projects, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cluster Headache Syndrome, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Center Laboratories Inc

Crossject SA

Eli Lilly and Co

Novartis AG

Teva Pharmaceutical Industries Ltd

TrioxBio Inc

I would like to order

Product name: Cluster Headache Syndrome - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/CFD01831E3BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CFD01831E3BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970